1048 related articles for article (PubMed ID: 19619699)
1. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
[TBL] [Abstract][Full Text] [Related]
2. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
[TBL] [Abstract][Full Text] [Related]
3. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
4. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
[TBL] [Abstract][Full Text] [Related]
5. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
6. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.
Backenköhler U; Erdogan A; Steen-Mueller MK; Kuhlmann C; Most A; Schaefer C; Stertmann W; Waas W; Tillmanns H; Waldecker B
J Cardiovasc Electrophysiol; 2005 May; 16(5):478-82. PubMed ID: 15877617
[TBL] [Abstract][Full Text] [Related]
7. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
[TBL] [Abstract][Full Text] [Related]
8. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
[TBL] [Abstract][Full Text] [Related]
9. Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT).
Borleffs CJ; van Erven L; Schotman M; Boersma E; Kiès P; van der Burg AE; Zeppenfeld K; Bootsma M; van der Wall EE; Bax JJ; Schalij MJ
Eur Heart J; 2009 Jul; 30(13):1621-6. PubMed ID: 19493865
[TBL] [Abstract][Full Text] [Related]
10. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
[TBL] [Abstract][Full Text] [Related]
11. Effect of first ventricular tachycardia cycle length on rate of ventricular arrhythmia recurrence in patients with implantable cardioverter-defibrillator.
Arya A; Haghjoo M; Nikoo MH; Dehghani MR; Fazelifar AF; Sadr-Ameli MA
J Electrocardiol; 2006 Oct; 39(4):404-8. PubMed ID: 16895771
[TBL] [Abstract][Full Text] [Related]
12. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
[TBL] [Abstract][Full Text] [Related]
15. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias.
Ypenburg C; van Erven L; Bleeker GB; Bax JJ; Bootsma M; Wijffels MC; van der Wall EE; Schalij MJ
J Am Coll Cardiol; 2006 Aug; 48(3):464-70. PubMed ID: 16875970
[TBL] [Abstract][Full Text] [Related]
16. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
17. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
[TBL] [Abstract][Full Text] [Related]
18. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
[TBL] [Abstract][Full Text] [Related]
19. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
Wilkoff BL; Hess M; Young J; Abraham WT
J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
[TBL] [Abstract][Full Text] [Related]
20. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
